Does exogenous glucose-dependent insulinotropic polypeptide (GIP) in combination with glucagon-like peptide-1 (GLP-1) attenuate the glycaemic response to small intestinal nutrient in critically ill patients?

The effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) in combination with glucagon-like peptide-1 (GLP-1) on glycaemia in critically ill patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000735954

Enrollment

Registered

2011-07-14

Start date

2011-08-25

Completion date

2012-04-19

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary objective of this study is to establish if exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 (both hormones released from the gastrointestinal tract) has a glucose lowering effect in critically ill patients

Interventions

Study Drug: Glucose-dependent insulinotropic polypeptide (GIP)at 2pmol.kg.min & glucagon-like peptide-1 (GLP-1) at 1.2pmol.kg.min Infused intravenously from 0-270mins or Control: 0.9% saline & GLP-1 at 1.2pmol/kg/min Infused intravenously from 0-270mins Patients will be studied on consecutive days (i.e. 24 hour washout period)

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

Mechanically ventilated critically ill patients. Suitable for, or receiving post-pyloric nutrition. Likely to stay ventilated for at least 48 hours.

Exclusion criteria

A history of diabetes. Pregnancy. Contraindication to placement of a post-pyloric feeding tube or enteral feeding. Previous surgery on the small intestine. Any gastrointestinal surgery during their current hospital admission.

Outcome results